Development, clinical utility, and place of ivacaftor in the treatment of cystic fibrosis

Drug Design, Development and Therapy

Volumn 7, Issue , 2013, Pages 929-937

  O'Reilly, Ruth ^a   Elphick, Heather E ^a  

^a SHEFFIELD CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

Cystic fibrosis; Cystic fibrosis transmembrane conductance regulator; Ivacaftor

Indexed keywords

ATALUREN; AZITHROMYCIN; CHLORIDE; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DORNASE ALFA; EPITHELIAL SODIUM CHANNEL; IVACAFTOR; LIPID; LUMACAFTOR; MESSENGER RNA; PLACEBO; PURINERGIC P2Y2 RECEPTOR STIMULATING AGENT; PURINERGIC RECEPTOR STIMULATING AGENT; RESPIRATORY TRACT AGENT; SHORT HAIRPIN RNA; TOBRAMYCIN; UNCLASSIFIED DRUG; VX 661; WATER;

BRONCHIECTASIS; CLASSIFICATION; CYSTIC FIBROSIS; DISEASE COURSE; DISEASE EXACERBATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DUCHENNE MUSCULAR DYSTROPHY; EVENING DOSAGE; FORCED EXPIRATORY VOLUME; GENE DELETION; GENE EXPRESSION; GENE MUTATION; GENE THERAPY; GENETIC DISORDER; GLY551ASP GENE; HUMAN; LUNG INFECTION; LUNG INJURY; LUNG INSUFFICIENCY; MORNING DOSAGE; NONHUMAN; PHE508DEL GENE; PHENOTYPE; PROTEIN DEFECT; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN STRUCTURE; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; RECURRENT INFECTION; RESPIRATORY TRACT DISEASE; REVIEW; RNA INTERFERENCE; WATER TRANSPORT; WEIGHT GAIN;

CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; IVACAFTOR;

AMINOPHENOLS; ANIMALS; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DRUG DESIGN; HUMANS; MOLECULAR TARGETED THERAPY; MUTATION; QUALITY OF LIFE; QUINOLONES;

EID: 84883377550     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S30345     Document Type: Review

References (62)

1. Farrell PM. The prevalence of cystic fibrosis in the European Union. J Cyst Fibros. 2008;7:450-453.
2. Kerem B, Rommens JM, Buchanan JA, et al. Identification of the cystic fibrosis gene: genetic analysis. Science. 1989;245:1073-1080.
3. Rommens JM, Iannuzzi MC, Kerem B, et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science. 1989;245: 1059-1065.
4. Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science. 1989;245:1066-1073.
5. Cystic Fibrosis Mutation Database. CFTR1, 2013. Available from: http://www.genet.sickkids.on.ca/cftr/ StatisticsPage.html. Accessed May 16, 2013.
6. Cystic Fibrosis Registry Report Trust. Annual Data Report 2010, December 2011. Available from: http://www.cftrust.org.uk/aboutcf/publications/cfregistryreports/UK_CF_Registry_-_Annual_Data_Report_2010.pdf. Accessed May 16, 2013.
7. Patient Registry. Annual Data Report. Bethesda, MD: Cystic Fibrosis Foundation; 2011. Available from: http://www.cff.org/LivingWithCF/QualityImprovement/PatientRegistryReport/. Accessed May 16, 2013.
8. Cohen-Cymberknoh M, Shoseyov D, Kerem E. Managing cystic fibrosis: strategies that increase life expectancy and improve quality of life. Am J Respir Crit Care Med. 2011;183:1463-1471.
9. Oxford University GeneMedicine. CFTR Protein Structure. Available from: http://www.genemedresearch.ox.ac.uk. Accessed April 20, 2013.
10. Bear CE, Li CH, Kartner N, et al. Purification and functional reconstitution of the cystic fibrosis transmembrane conductance regulator (CFTR). Cell. 1992;68:809-818.
11. Gadsby DC, Vergani P, Csanady L. The ABC protein turned chloride channel whose failure causes cystic fibrosis. Nature. 2006;440:477-483.
12. Knowles M, Gatzy J, Boucher R. Increased bioelectric potential difference across respiratory epithelia in cystic fibrosis. N Engl J Med. 1981;305:1489-1495.
13. Mall M, Grubb BR, Harkema JR, O'Neal WK, Boucher RC. Increased airway epithelial Na+ absorption produces cystic fibrosis-like lung disease in mice. Nat Med. 2004;10:487-493.
14. Farrell PM, Rosenstein BJ, White TB, et al. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. J Pediatr. 2008;153:S4-S14.
15. Kerem B, Chiba-Falek O, Kerem E. Cystic fibrosis in Jews: frequency and mutation distribution. Genet Test. 1997;1:35-39.
16. McKone EF, Emerson SS, Edwards KL, Aitken ML. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. Lancet. 2003;361:1671-1676.
17. Hamosh A, King TM, Rosenstein BJ, et al. Cystic fibrosis patients bearing both the common missense mutation Gly-Asp at codon 551 and the delta F508 mutation are clinically indistinguishable from delta F508 homozygotes, except for decreased risk of meconium ileus. Am J Hum Genet. 1992;51:245-250.
18. Highsmith WE, Burch LH, Zhou Z, et al. A novel mutation in the cystic fibrosis gene in patients with pulmonary disease but normal sweat chloride concentrations. N Engl J Med. 1994;331:974-980.
19. Kulczycki LL, Kostuch M, Bellanti JA. A clinical perspective of cystic fibrosis and new genetic findings: relationship of CFTR mutations to genotype-phenotype manifestations. Am J Med Genet A. 2003;116A: 262-267.
20. Davis PB, Schluchter MD, Konstan MW. Relation of sweat chloride concentration to severity of lung disease in cystic fibrosis. Pediatr Pulmonol. 2004;38:204-209.
21. McKone EF, Goss CH, Aitken ML. CFTR genotype as a predictor of prognosis in cystic fibrosis. Chest. 2006;130:1441-1447.
22. de Gracia J, Mata F, Alvarez A, et al. Genotype-phenotype correlation for pulmonary function in cystic fibrosis. Thorax. 2005;60:558-563.
23. Shoshani T, Augarten A, Gazit E, et al. Association of a nonsense mutation (W1282X), the most common mutation in the Ashkenazi Jewish cystic fibrosis patients in Israel, with presentation of severe disease. Am J Hum Genet. 1992;50:222-228.
24. Rowntree RK, Harris A. The phenotypic consequences of CFTR mutations. Ann Hum Genet. 2003;67:471-485.
25. Van Goor F, Straley KS, Cao D, et al. Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. Am J Physiol Lung Cell Mol Physiol. 2006;290: L1117-L1130.
26. Clinical and Functional Translation of CFTR. CFTR2. Available from: http://www.cftr2.com. Accessed January 19, 2013.
27. Oakland M, Sinn PL, McCray PB Jr. Advances in cell and gene-based therapies for cystic fibrosis lung disease. Mol Ther. 2012;20:1108-1115.
28. The UK Cystic Fibrosis Gene Therapy Consortium. Gene therapy multi-dose clinical trial. Available from: http://www.cfgenetherapy.org.uk. Accessed April 20, 2013.
29. Carlile GW, Robert R, Zhang D, et al. Correctors of protein trafficking defects identified by a novel high-throughput screening assay. Chembiochem. 2007;8:1012-1020.
30. Galietta LV, Jayaraman S, Verkman AS. Cell-based assay for high-throughput quantitative screening of CFTR chloride transport agonists. Am J Physiol Cell Physiol. 2001;281:C1734-C1742.
31. Van Goor F, Hadida S, Grootenhuis PD, et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci U S A. 2009;106:18825-18830.
32. Eckford PD, Li C, Ramjeesingh M, Bear CE. Cystic fibrosis transmembrane conductance regulator (CFTR) potentiator VX-770 (ivacaftor) opens the defective channel gate of mutant CFTR in a phosphorylation-dependent but ATP-independent manner. J Biol Chem. 2012;287:36639-36649.
33. Ramsey BW, Davies J, McElvaney NG, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011;365:1663-1672.
34. Vertex Pharmaceuticals. Kalydeco©. Available from: http://www.ema.europa.eu/docs/en_GB/document_library. Acessed January 20, 2013.
35. [No authors listed]. Ivacaftor (Kalydeco) for cystic fibrosis. Med Lett Drugs Ther. 2012;54:29-30.
36. De Boeck K, Kent L, Davies J, et al. CFTR biomarkers: time for promotion to surrogate end-point. Eur Respir J. 2013;41:203-216.
37. Konstan MW, Wagener JS, Yegin A, Millar SJ, Pasta DJ, Vandevanter DR. Design and powering of cystic fibrosis clinical trials using rate of FEV(1) decline as an efficacy endpoint. J Cyst Fibros. 2010;9:332-338.
38. Que C, Cullinan P, Geddes D. Improving rate of decline of FEV1 in young adults with cystic fibrosis. Thorax. 2006;61:155-157.
39. Durmowicz AG, Witzmann KA, Rosebraugh CJ, Chowdhury BA. Change in sweat chloride as a clinical end point in cystic fibrosis clinical trials: the ivacaftor experience. Chest. 2013;143:14-18.
40. US Food and Drug Administration. Notification to the Cystic Fibrosis Community on Kalydeco (ivacaftor). Available from: http://www.fda.gov/Drugs/DrugSafety. Accessed April 20, 2013.
41. Bush A, Simmonds NJ. Hot off the breath: 'I've a cost for'-the 64 million dollar question. Thorax. 2012;67:382-384.
42. Fuchs HJ, Borowitz DS, Christiansen DH, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med. 1994;331:637-642.
43. Equi A, Balfour-Lynn IM, Bush A, Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet. 2002;360:978-984.
44. Yu H, Burton B, Huang CJ, et al. Ivacaftor potentiation of multiple CFTR channels with gating mutations. J Cyst Fibros. 2012;11:237-245.
45. Davis PB, Yasothan U, Kirkpatrick P. Ivacaftor. Nat Rev Drug Discov. 2012;11:349-350.
46. Flume PA, Liou TG, Borowitz DS, et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation. Chest. 2012;142:718-724.
47. Van Goor F, Hadida S, Grootenhuis PD, et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc Natl Acad Sci U S A. 2011;108:18843-18848.
48. Zhang L, Button B, Gabriel SE, et al. CFTR delivery to 25% of surface epithelial cells restores normal rates of mucus transport to human cystic fibrosis airway epithelium. PLoS Biol. 2009;7:e1000155.
49. Clancy JP, Rowe SM, Accurso FJ, et al. Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax. 2012;67:12-18.
50. Boyle M. The investigational CFTR corrector, VX-809, co-administered with the oral potentiator ivacaftor improved CFTR and lung function in F508del homozygous patients: Phase 2 study results. Poster 260 presented at the 26th North American Cystic Fibrosis Conference, Orlando, FL, October 11-13, 2012.
51. ClinicalTrials. gov. Study of VX-661 alone and in combination with VX-770 in subjects homozygous to the F508del-CFTR mutation. Available from: http://clinicaltrials.gov/show/NCT01531673. Accessed April 20, 2013.
52. Vertex. Treatment with VX-661 and ivacaftor in a Phase 2 study resulted in statistically significant improvements in lung function in people with cystic fibrosis who have two copies of the F508del mutation. Available from: http://investors.vrtx.com/releasedetail.cfm?releaseid=757597. Accessed April 20, 2013.
53. Welch EM, Barton ER, Zhuo J, et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature. 2007;447:87-91.
54. Kerem E, Hirawat S, Armoni S, et al. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet. 2008;372:719-727.
55. Clancy JP, Rowe SM, Bebok Z, et al. No detectable improvements in cystic fibrosis transmembrane conductance regulator by nasal aminoglycosides in patients with cystic fibrosis with stop mutations. Am J Respir Cell Mol Biol. 2007;37:57-66.
56. Kerem E, Wilschanski M, De Boeck K, et al. Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. J Cyst Fibros. 2011;10:S17.
57. PTC Therapeutics Inc. Top-line data from phase 3 trial of ataluren in patients with nonsense mutation cystic fibrosis show promising results. Available from: http://ptct.Client.Shareholder.Com/releasedetail. Accessed January 26, 2013.
58. Mendell JR, Rodino-Klapac L, Sahenk Z, et al. Gene therapy for muscular dystrophy: lessons learned and path forward. Neurosci Lett. 2012;527:90-99.
59. Hyde SC, Painter H, Gill DR. EnaC knockdown in the mouse lung using RNAI. Pediatr Pulmonol. 2007;42:306.
60. Harding-Smith RE, Gill DR, Hyde SC. Knockdown of ENaCá, as a treatment for cystic fibrosis lung disease. Mol Ther. 2011;19:1360-1398.
61. Wang X, Venable J, LaPointe P, et al. Hsp90 cochaperone Aha1 downregulation rescues misfolding of CFTR in cystic fibrosis. Cell. 2006;127:803-815.
62. Hutt DM, Herman D, Rodrigues AP, et al. Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis. Nat Chem Biol. 2010;6:25-33.